CDP870 in Crohn's disease: reconsidering endpoints
- PMID: 16534429
- DOI: 10.1097/01.MIB.0000202557.16581.42
CDP870 in Crohn's disease: reconsidering endpoints
Comment on
-
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.Gastroenterology. 2005 Sep;129(3):807-18. doi: 10.1053/j.gastro.2005.06.064. Gastroenterology. 2005. PMID: 16143120 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical